Chronic pruritus of unknown origin (CPUO): Uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment - 11/10/19

Doi : 10.1016/j.jaad.2019.06.038

Brian S. Kim, MD, MTR ^a,^b,^c,^d, Timothy G. Berger, MD ^e, Gil Yosipovitch, MD ^f,^⁎
^a Center for the Study of Itch, Washington University School of Medicine in St Louis, St Louis, Missouri
^b Division of Dermatology, Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri
^c Department of Anesthesiology, Washington University School of Medicine in St Louis, St Louis, Missouri
^d Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri
^e Department of Dermatology, University of California, San Francisco, California
^f Miami Itch Center, Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida

^∗Correspondence to: Gil Yosipovitch, Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, 1600 NW 10th Ave, Miami FL 33136.Dr Phillip Frost Department of Dermatology and Cutaneous SurgeryUniversity of MiamiMiller School of Medicine1600 NW 10th AveMiamiFL33136

Le texte complet de cet article est disponible en PDF.

Funding sources: Dr Kim was supported by grants from the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR-070116, K08-AR-065577), the Doris Duke Charitable Foundation, the American Skin Association, and LEO Pharma. Dr Yosipovitch was supported by grants from Sun Pharma and LEO Pharma.

Conflicts of interest: Dr Kim has served as a consultant for AbbVie, Inc, Concert Pharmaceuticals, Incyte Corporation, Menlo Therapeutics, and Pfizer, Inc; is stockholder, founder, and chief scientific officer of Nuogen Pharma, Inc; and has participated on advisory boards for Cara Therapeutics, Celgene Corporation, Kiniksa Pharmaceuticals, Menlo Therapeutics, Regeneron Pharmaceuticals, Inc, Sanofi, and Theravance Biopharma. Dr Berger has participated on advisory boards for Menlo Therapeutics, Pfizer, and Sanofi. Dr Yosipovitch has participated on advisory boards for AbbVie, Inc, Bayer, Cerave, Galderma, Kiniksa, Menlo Therapeutics, Ortho, Pfizer, Sanofi Regeneron, Trevi Therapeutics, Novartis, Eli Lilly, and Sienna Biopharmaceuticals.